Use of Camrelizumab for Injection in a Hospital from 2021 to 2023
Objective To provide a reference for the rational use of Camrelizumab for Injection in clinical practice.Methods The data of patients who used Camrelizumab for Injection in the Shexian Branch of the Second Affiliated Hospital,Zhejiang University School of Medicine from January 2021 to December 2023 were extracted by the PASSPharmAssist,GOODWILL Electronic Medical Record System and Hospital Information System.The drug use evaluation(DUE)criteria for Camrelizumab for Injection was formulated,on this basis,the types of irrational medical orders were analyzed.Results A total of 313 patients were collected,with more males(243 cases,77.64%)than females(70 cases,22.36%),aged in the range of 33-93 years,with the majority being over 65 years(189 cases,60.38%).Medical orders(1615 ones)mainly involved medical oncology department(1378 orders,85.33%);Camrelizumab for Injection was mainly used to treat hepatocellular malignancy(441 orders,27.31%)and esophageal malignancy(437 orders,27.06%).The main types of irrational medical orders were no gene test before medication(106 orders,6.56%),inappropriate indications(83 orders,5.14%),incomplete information on dosage(10 orders,0.62%),and inappropriate infusion sequence(seven orders,0.43%);the proportion of medical orders with the above irrationalities except incomplete information on dosage in medical oncology department was significantly different from that in non-medical oncology department(P<0.05).Conclusion The clinical use of Camrelizumab for Injection in this hospital is generally rational.However,clinical physicians still need to strengthen their knowledge of drug instructions or authoritative evidence-based medical evidence,pharmacists need to strengthen the real-time review of medical orders,and the hospital should strengthen the information construction of quality control to promote the rational drug use.
Camrelizumab for Injectionrational drug userationality evaluationdrug use evaluation
国家科技期刊平台
NSTL
万方数据
